18018 Background: Erlotinib significantly improved survival versus placebo and was well
tolerated in patients (pts) with previously treated advanced NSCLC in the phase III BR. 21 …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

19001 Background: The open-label, global phase IV TRUST study provided erlotinib for pts
with advanced NSCLC. Methods: Eligible pts had stage IIIB/IV NSCLC and had either failed …

Methods An open labeled, expanded access program (EAP) was conducted on 44
pathologically confirmed advanced NSCLC patients who had received at least one regimen …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Background: In the BR. 21 phase III placebo-controlled study (Shepherd et al. NEJM 2005;
353: 123-132), erlotinib (Tarceva®) was well tolerated and significantly improved survival …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …